名稱(chēng) | FOXP3 promoter-Luc/Jurkat |
型號(hào) | CBP74011 |
報(bào)價(jià) | |
特點(diǎn) | FOXP3 promoter-Luc/Jurkat,凍存條件:90% FBS+10% DMSO; |
產(chǎn)品搜索
產(chǎn)品分類(lèi)
相關(guān)文章
聯(lián)系我們
聯(lián)系人:蔣經(jīng)理
電話:4008750250
號(hào)碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號(hào)
Email: zhangxiangwen@cobioer.com
電話:4008750250
號(hào)碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號(hào)
Email: zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > 腫瘤免疫細(xì)胞株 > CBP74011FOXP3 promoter-Luc/Jurkat
- 詳細(xì)內(nèi)容
CBP74011 | |
I. Background | |
Foxp3, belonging to the forkhead family, is a master transcription factor that expresses exclusively in regulatory T cells, a subset of CD4+ T cells. Regulation of Foxp3 is critical for maintaining immunological tolerance. Over-expression of Foxp3 is known to suppress effector T cell activation. | |
II. Description | |
Human Foxp3 luciferase reporter construct is stably integrated into the genome of Jurkat T- cells. The firefly luciferase gene is controlled by a human Foxp3 promoter and an enhancer-like conserved noncoding sequence upstream of the Foxp3 promoter. Figure 1. Illustration of Foxp3 promoter region with representative transcription factor binding sites and enhancer regions. | |
III. Introduction | |
Host Cell: | Jurkat |
Expressed gene: | Foxp3-Luciferase |
Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Synonym(s): | Foxp3, Foxp3 cell line, scurfin cell line, foxo |
Freeze Medium: | 90% FBS+10% DMSO |
Culture Medium: | RPMI-1640+10%FBS+1 ug/ml puromucin |
Storage: | Liquid nitrogen |
Application(s): | Functional(Report Gene) Assay |
IV. Description of Host Cell Line | |
Organism: | Homo sapiens, human |
Tissue: | Peripheral blood |
Disease: | Acute T cell leukemia |
Morphology: | Lymphoblast |
Growth Properties: | Suspension |
Ⅴ. Representative Data | |
Figure 2. Detect Luciferase assay by Ultra Luciferase Detection Kit CBPH0001(we strongly suggest to purchase from Cobioer). Foxp3 Jurkat Reporter Activity in response to PMA with lonomycin. |